Customers Endorse Elsevier’s Inteleos on the Eve of First Anniversary

In a Recent Survey, 88% of Customers Stated That They Would Recommend the Drug Tracking and Analysis Tool to Colleagues and Peers

Amsterdam, 15 May 2007 – Elsevier, a world-leading healthcare and scientific publisher, announced today the first year anniversary of Inteleos, its drug tracking and analysis tool that supports decision-making and business strategy for business intelligence professionals.

Inteleos has received overwhelmingly positive responses from the industry since its launch. The survey results provide further validation that Inteleos is the most intuitive, flexible tool for drug pipeline research, tracking and analysis.

In addition to gauging customer satisfaction, the survey solicited feedback on new product development. "I am very pleased that so many Inteleos customers are willing to endorse the product, but I'm even more enthusiastic about the prospect of applying their feedback to the next generation of development for Inteleos, says Health Sciences CEO, Brian Nairn.

The Inteleos development and editorial teams will continue to build on the product's strengths and provide enhanced indexing to meet today's scientific challenges. The coverage of biologics, together with the most comprehensive coverage of FDA (and soon EMEA) regulatory filings in the drug pipeline product sector, makes Inteleos an invaluable resource.

The anniversary is the first in a series of milestones for Inteleos. "By listening to our customers and other business intelligence professionals, we have been able to create an exciting development plan for Inteleos that will be rolled out throughout 2007," reports Director of Emerging Products, Julie Gordon. "New content and enhanced functionality will make it even easier for our customers to make informed business decisions."

Inteleos will be demonstrated at the Special Libraries Association (SLA), the World Pharmaceutical Congress (WPC) and the Drug Information Association (DIA) in June.
For more information go to

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

Media Contact:
Paula Reeves
The Reeves Agency
+31 (0) 20 305 1380